More than 60% of patients with lung cancer are diagnosesd at advanced stages. The introduction of targeted therapies requires molecular diagnosis to guide treatment. The aim of this study was to evaluate the feasibility of performing mutational analysis with brushing specimens obtained by radial-miniprobe endobronchial ultrasound (R-EBUS) plus fluoroscopy-guided bronchoscopy in patients with peripheral pulmonary adenocarcinoma. METHODS:
INTRODUCTION
The carcinogenesis process, known as the multihit and multistep model, suggests that patients with an intrinsic susceptibility after repeated exposure to injurious factors are susceptible to gaining specific somatic driver alterations that trigger clonal cell expansion. Lung adenocarcinoma and squamous cell carcinoma present an important mutational burden in comparison with other cancers, but in the former, the genomic alterations in oncogenes considered to be therapeutically targetable predominate. 1 The International Association for
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the Study of Lung Cancer recommends molecular testing in all patients with advanced-stage adenocarcinoma or tumors with an adenocarcinoma component for the detection of epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK ) rearrangements to guide patient therapy. 2 Recent evidence suggests that the assessment should be extended to ROS1 fusions, BRAF mutations, and MET amplifications. [3] [4] [5] [6] To date, the US Food and Drug Administration has approved genome-guided therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations, ALK rearrangements, or ROS1 fusions, and most recently, a dabrafenibtrametinib combination was approved for metastatic NSCLC with BRAF V600E mutations. 3, 7 The genotyping and phenotyping of lung adenocarcinoma, which are fundamental for determining a more precise classification and for guiding therapy, are not easily accessible in standard clinical practice because of the need for large tissue samples to identify the tumor origin with immunohistochemical techniques and perform adequate genetic profiling. Invasive techniques such as surgery are frequently required to obtain tumor samples even though multiple studies have confirmed the efficacy of less invasive techniques such as endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration, radial-miniprobe endobronchial ultrasound (R-EBUS)-guided transbronchial biopsy, and blood liquid biopsy in the detection of the most frequent molecular alterations in lung cancer. [8] [9] [10] [11] [12] [13] The practice of EBUS was first described in 1992 when Hurter and Hanrath 14 obtained ultrasonic tomography images of the contiguous tissues around the bronchus and trachea while using a vascular ultrasound catheter (lineal probe) during bronchoscopy. Since then, R-EBUS and later EBUS-guided transbronchial needle aspiration with a convex probe have become routine procedures in the study of pulmonary disease, mainly in lung cancer. [15] [16] [17] Nevertheless, the diagnosis of peripheral pulmonary lesions (PPLs) is still a challenge in clinical practice because of the difficulty of approaching them with standard bronchoscopy and because of the need to obtain large samples for pathological and molecular diagnoses. 18 R-EBUS-guided transbronchial biopsy using fluoroscopy has proven to be the most effective noninvasive techniques for the pathological diagnosis of peripheral lung nodules, and the molecular profiling of these samples seems to be feasible when biopsy or cell blocks can be performed. [19] [20] [21] [22] The aims of the current study were to explore the feasibility of performing mutational profiling of Kirsten rat sarcoma viral oncogene homolog (KRAS) and EGFR genes with brush cytology obtained by R-EBUS plus fluoroscopy and to determine its correlation with the molecular results of histological samples in patients with peripheral lung adenocarcinoma.
MATERIAL AND METHODS

Subjects
A prospective study was performed; it included all patients with PPLs detected by a computed tomography (CT) scan of the lungs who were candidates for flexible bronchoscopy at Hospital del Mar-Parc de Salut Mar, a tertiary teaching hospital in Barcelona, Spain, from July 2015 to July 2017. In all cases, a CT scan of the lungs, mediastinum, and upper abdomen was performed in the month before inclusion in the study (multidetector row spiral CT scan; Sensation 4 and Sensation 16; Siemens, Erlangen, Germany). All patients were evaluated with R-EBUS guided by fluoroscopy, and if possible, cytological brushing and transbronchial biopsy were performed to reach a diagnosis (Fig. 1) . A PPL was defined as a pulmonary lesion surrounded by lung parenchyma and not endoscopically visible by bronchoscopy. All patients agreed to participate, and the research protocol was approved by the regional ethics committee (Ethics Committee for Clinical Research of the Parc de Salut Mar). Finally, all patients with a diagnosis of adenocarcinoma were included, and molecular testing for EGFR and KRAS was performed with the waste brushing specimens. If a definitive diagnosis was not made by bronchoscopy, invasive procedures such as percutaneous lung biopsy and surgical biopsy were performed to establish the final diagnosis. The pathological classification of lung cancer was made on the basis of the new criteria proposed by the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society.
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R-EBUS Guided by Fluoroscopy and Sample Processing
The bronchoscopy was performed with a flexible bronchoscope (BF Q-180; Olympus, Tokyo, Japan) via the transnasal route in our respiratory endoscopy room, Cancer Cytopathology October 2018 which was equipped with a fluoroscopy unit. Local anesthesia and conscious sedation with propofol and remifentanil were used and supervised by an anesthesiologist. The bronchial tree in both lungs was examined down to the level of subsegmental bronchi. Subsequently, a UM-S20-17S radial ultrasound miniprobe (Olympus) with an SG-200C guide sheath (Olympus) was inserted through the working channel of the bronchoscope and advanced to the target subsegmental bronchi until the lesion was located on EBUS and fluoroscopy images. The EBUS miniprobe was then moved within the lesion under fluoroscopic control to identify the most suspicious area to obtain the tissue specimens. Next, the probe was withdrawn under fluoroscopy, and the guide sheath was left in place. A bronchial brush was introduced through the guide sheath to obtain samples from the site marked by fluoroscopy. Three brushings (BC-204D-2010 disposable cytology brush; Olympus) for cytological smears and 1 brushing for molecular smears were performed.
Cytomorphological slides for routine evaluation were obtained as usual and were evaluated by a cytopathologist for diagnosis. After preparation for direct smears, waste brushing samples, including those remaining on the brush head, are usually discarded; however, in our study, the brush head was cut and immersed in a conical tube containing 15 mL of Roswell Park Memorial Institute (RPMI) culture medium to preserve cell viability and stability. Before DNA extraction, vortexing was performed for 2 minutes to release the maximum number of cells from the brush. Then, the medium with released cells was transferred to a new sterile conical tube and was centrifuged for 10 minutes at 2300 rpm. The supernatant was discarded, and DNA was extracted from the pellet of cells with the QIAamp mini kit (Qiagen, Hilden, Germany). Histological specimens, including surgical tissues and small biopsy samples, were formalin-fixed and paraffin-embedded. Every specimen was revised by the pathologist to select the area enriched with tumor cells by manual macrodissection. Two sections of 20 µm were obtained, and DNA was extracted with the QIAamp mini kit (Qiagen).
EGFR and KRAS Status in Cytological and Histological Specimens
The EGFR mutational status was analyzed by real-time polymerase chain reaction (PCR) with the Therascreen EGFR RGQ PCR kit (Qiagen), a highly sensitive assay based on ARMS Scorpions real-time PCR technology that detects 29 different somatic mutations. In addition, exons 18 to 21 of the EGFR gene and exon 2 of the KRAS gene were analyzed in all cases by Sanger sequencing with BigDye v3.1 (Applied Biosystems, Foster City, California) in a 3500DX genetic analyzer (Applied Biosystems). In cases in which discordant results in the EGFR mutational status were observed between cytological and histological samples, competitive allele-specific TaqMan polymerase chain reaction (castPCR; Life Technologies) was used.
Statistical Analysis
Data were collected and analyzed with SPSS for Windows (version 21.0; IBM Corporation, Armonk, New York). Categorical variables were described as frequencies and percentages, and continuous variables were expressed as means and standard deviations. Intra-individual agreement between the different methods used to detect EGFR and KRAS mutations was determined via the calculation of Cohen's κ coefficient. A P value < .05 was considered statistically significant.
RESULTS
Patient Characteristics
A total of 108 patients with PPLs who underwent bronchoscopy were included in the study. In 91 cases, a malignant lesion was identified, and 17 patients showed benign lesions. We performed R-EBUS plus fluoroscopyguided bronchoscopy in 71 patients with a final diagnosis of malignancy. In these patients, the PPL was localized by R-EBUS plus fluoroscopy-guided bronchoscopy, and bronchial brushing with or without transbronchial biopsy was performed in 43 patients (60%). A comprehensive molecular study was performed in 30 patients with a definitive diagnosis of adenocarcinoma.
The mean age of the participants was 66 ± 11 years, with 26.7% being female. The majority of patients were current or former smokers (79.9%), with a clear predominance in men (90.9%), whereas half of the women had never smoked. The patients presented with a mean PPL diameter of 45.4 ± 22 mm, and all of them had at least 1 comorbidity with a predilection for the upper lobes (see Table 1 ).
The overall diagnostic yield of R-EBUS plus fluoroscopy-guided bronchoscopy was 70.5% (95% confidence interval, 72.9%-87.8%). There were no major complications in our study during or after the procedure, and there were no cases of pneumothorax. Minimal self-limiting bleeding was occasionally observed.
EGFR and KRAS Mutations in Brushing Samples
The mutational study of KRAS and EGFR genes was feasible in all cases with brush cytology and the RPMI reagent. The quantification of the DNA concentration (obtained with a Nanodrop spectrophotometer) showed a median DNA concentration of 29.35 ng/µL (range, 13.9-88.2 ng/µL), and a molecular complementary diagnosis was performed in all cases (Table 2) . A mutation in either the KRAS or EGFR gene was detected in 16 patients Abbreviations: COPD, chronic obstructive pulmonary disease; Dlco, diffusing capacity of lung for carbon monoxide; FEV 1 , forced expiratory volume in the first second of expiration; FVC, forced vital capacity; RV, residual volume; SD, standard deviation; TLC, total lung capacity.
Cancer Cytopathology October 2018 (53.3%): 10 (33.3%) were KRAS-positive, and 6 (20%) were EGFR-positive, with 2 patients carrying 2 different EGFR mutations (patients 13 and 21). Histological samples were also obtained in 15 cases; the correlation between brush cytology and biopsy specimens was 86.6% with a κ value of 0.737 (P < .001), and only 2 patients (patients 18 and 22) showed a wild-type profile in the brush cytology but were EGFR-mutated (p.E746_A750 and p.T751_I759delinsN, respectively) in the histological specimen (Tables 2 and 3 ). These 2 discordant cases were further analyzed with castPCR, which has higher sensitivity because this PCR strategy is based on the blockade of the wild-type allele. We were able to obtain a positive result in both cases, and this indicated that tumor DNA was present in the samples.
The 
DISCUSSION
We have demonstrated that brushing specimens obtained by EBUS plus fluoroscopy-guided bronchoscopy and collected in the RPMI medium provide a useful material for performing molecular testing (ie, EGFR and KRAS mutational analysis in our study) in patients with peripheral lung adenocarcinoma. Brushing specimens usually contain few tumor cells, and in samples with limited tumor cellularity, molecular testing may be challenging because an adequate amount of tumor genomic DNA is not always available. 24 Nevertheless, the high rate (100%) of successful mutational analysis in this study suggests that although a limited amount of DNA is obtained from brushing specimens, it is sufficient to perform PCRbased methods.
We collected brush samples in the RPMI medium. The original formulation of this solution was published by Moore et al 25 and is routinely used in cell and tissue culture. We have used it to collect brushing samples with the aim of preserving cell viability and optimizing conservation of the samples. Genetic analysis is normally performed with genomic DNA, which is present in all nucleated cells, but PCR-based Sanger sequencing with genomic DNA is limited by lower sensitivity in the detection of somatic mutations in samples with a large quantity of nontumor cells. 12 Unlike traditional Sanger sequencing, next-generation sequencing includes PCR-based techniques that capture a wider spectrum of mutations but require a minimum of 1000 cells in formalin-fixed, paraffin-embedded samples (5-10 ng of tool DNA). 26 For nonsurgical specimens, which include small biopsy samples and cytology samples, the success rate for EGFR genotyping ranges from 83% to 100% according to series and if enough tumor cells are present. 27 When nontumor or low-density cell samples with an expected low abundance of mutations require molecular testing, allele-specific real-time PCR and Scorpion assays (amplification refractory mutation system) are excellent options 28 but with the limitation of a higher cost, and only predetermined mutations available in the commercial kit can be detected. In our study, we used allele-specific real-time PCR technology for the detection of 29 different somatic mutations plus Sanger sequencing to perform highly sensitive molecular testing of a broader spectrum of mutations in a low-density cell sample with excellent results. Tsai et al 12 applied RNA-based reverse transcription-polymerase chain reaction (RT-PCR) and Sanger sequencing to waste brushing samples and successfully detected EGFR (55%) and KRAS mutations (2.5%); this suggests that this method is promising for this specific Cancer Cytopathology October 2018 type of biological specimen. RT-PCR-based methods using RNA as the amplification template take advantage of the differential expression of the target oncogene, which is enriched in the RNA template derived from tumor cells in biological samples. In addition, the dilution of the wild-type RNA content from nontumor cells can be minimized. This biological context could inherently prevent the interference of nontumor cells in heterogeneous specimens and, therefore, explain the sensitivity of RT-PCR-based systems in the analysis of oncogenic mutations even with traditional Sanger sequencing. 11 In another study, Guisier et al 20 could achieve the molecular analysis in 15 of 27 patients (55.6%) for whom brushing alone was positive for malignancy and in 12 of 15 patients (80%) for whom biopsies alone were positive for cancer. The molecular analysis of the current series included the EGFR and KRAS genes. We found molecular abnormalities in 16 of the 30 patients (53.3%). The sensitivity of the molecular analysis cannot be entirely assessed in this series because resampling to obtain histological tissue was available for only 15 of the 30 patients. Nevertheless, the sensitivity appears very high because 13 of these 15 patients (86.7%) initially confirmed the results of R-EBUS plus fluoroscopy-guided sampling, and this percentage rose to 100% when higher sensitivity techniques were applied. Moreover, the KRAS (33.3%) and EGFR mutation rates (25.7%) in our series are consistent with those described in the literature, in which mutation rates of 33% and 10% to 16% for KRAS and EGFR, respectively, have been reported. When histological samples were also obtained, the correlation between brush cytology and biopsy specimens was 86.6%, and this is consistent with the results of previous studies 29 ; also, only 2 patients with EGFR mutations in the histological specimens presented initially with a wild-type profile in the brush cytology samples. However, the application of high-sensitivity techniques such as castPCR showed the presence of the EGFR mutations and, therefore, confirmed the presence of tumor tissue and confirmed the utility of this sampling method for molecular testing. In case 18, the false-negative result could be due to the fact that the histological specimen was from hepatic metastases. Italiano et al 30 demonstrated that a significant proportion of patients with NSCLC showed discordance between the primary tumor and its metastasis in the EGFR mutational status, and this suggests that EGFR expression might not be stable during the progression of metastasis. Moreover, there are studies of heterogeneity in different tumors that have demonstrated extensive genetic and epigenetic variability at different metastasis sites. 
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Obtaining histological samples is not always possible. In fact, in our study, it was possible to obtain a concomitant biopsy sample for only 15 of 30 cases. This was mainly due to the aggressiveness of the procedure in the patients, most of whom had emphysema and a major risk of pneumothorax, and due to the difficulties of the technique, with most of the lesions being in the upper lobes (80%). On the other hand, there is increasing demand for larger samples obtained via minimally invasive techniques to perform widespread molecular testing in patients affected with NSCLC to guide therapeutic decision making. This is a huge challenge for pulmonologists, oncologists, and pathologists that forces us to optimize the specimens and determine the most accurate molecular testing. We should not forget that with the great advances in immunotherapy, histological/cytological samples will serve not only for cellular diagnosis or molecular testing but also for the detection of PD-L1 expression to guide immunotherapy.
For all these reasons, we believe that this novel approach is very promising for performing mutational testing in patients with peripheral lung adenocarcinoma. Currently, mutational profiling plays a key role in determining the best therapeutic strategy for the patient, but this mutational profiling is frequently difficult to perform, especially in patients with lung adenocarcinoma, because of the small amount of histological samples available. Although new approaches are currently being investigated to perform mutational testing, such as the obtention and analysis of circulating tumor DNA 
(known as liquid biopsy), the use of brush cytology could also be a promising and effective strategy for performing these studies. Nevertheless, obtaining tumor cytological samples by R-EBUS guided by fluoroscopy in peripheral tumors is a challenge, and even though we have optimized the technique, its highest sensitivity for diagnosis, depending on the size of the lesion, varies between 78% and 90%. In addition, it has to be taken into account that a low concentration of tumor DNA may be obtained in cytological samples obtained by brushing, so the use of techniques with high sensitivity is highly recommended.
Our results should be interpreted in light of the limitations of our study: the matched specimens for comparing the EGFR and KRAS mutation status were not obtained exclusively from R-EBUS transbronchial biopsies, and the study was conducted at a single institution. Multicenter studies remain under consideration.
In conclusion, the current study has demonstrated that brushing specimens conserved in the RPMI medium and obtained by R-EBUS plus fluoroscopy-guided bronchoscopy are useful for detecting EGFR and KRAS mutations in patients with peripheral lung adenocarcinoma via DNA-based real-time PCR and Sanger sequencing. 
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